Cardiovascular diseases, particularly heart disease with comorbid hypertension, represent a major contributor to increased morbidity, mortality, and healthcare costs, especially among hospitalized patients covered by the Indonesian National Health Insurance (BPJS) in referral hospitals. Long-term heart failure therapy involving multiple drug combinations leads to substantial direct medical costs, highlighting the need for cost-effectiveness evaluation. This study aimed to analyze the cost-effectiveness of pharmacological therapy in hospitalized heart failure patients with comorbid hypertension at RSUD Arifin Achmad, Pekanbaru. This study employed a descriptive quantitative design with a retrospective approach using pharmacoeconomic Cost-Effectiveness Analysis (CEA). Cost-effectiveness was assessed using the Average Cost-Effectiveness Ratio (ACER). A total of 58 patients met the inclusion criteria. The most frequently prescribed therapies were combinations of angiotensin receptor blockers (ARB) with calcium channel blockers (CCB) and diuretics with angiotensin-converting enzyme inhibitors (ACEI) and antiplatelet agents (aspilets), each accounting for 12.06%. Most treatment regimens demonstrated high clinical effectiveness in achieving blood pressure targets. The lowest ACER value was observed in the combination of diuretics, ARB, and β-blockers, amounting to Rp13,950, indicating this regimen as the most cost-effective therapy. The combination of diuretics, ARB, and β-blockers represents the most clinically effective and economically efficient treatment option for hospitalized heart failure patients with comorbid hypertension.
Copyrights © 2026